IMPROVEMENT IN INFLAMMATORY BIOMARKER LEVELS THROUGH WEEK 12 IN MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS PATIENTS TREATED WITH GUSELKUMAB: RESULTS FROM THE PHASE 3 QUASAR INDUCTION STUDY

Tadakazu Hisamatsu  ¹     Laurent Peyrin-Biroulet  ²     Axel Dignass  ³     Gary KH Huang  ⁴     Matthew Germinaro  ⁴     Nicole Houck  ⁴     Ye Miao  ⁴     Hongyan Zhang  ⁴     Marjorie Costa Argollo  ⁵     Ken Takeuchi  ⁶     Rafal Filip  ⁷     Jessica Allegretti  ⁸     Brian G. Feagan  ⁹     Bruce E. Sands  ^10    
1 Kyorin University, Tokyo, Japan
² Nancy University Hospital, Université de Lorraine, Nancy, France
³ Agaplesion Markus Hospital, Goethe University, Frankfurt, Germany
⁴ Janssen Research & Development, LLC, Spring House, United States
⁵ Onco Star SP Oncologia Ltda, Sao Paulo, Brazil
⁶ Tsujinaka Hospital Kashiwanoha, Kashiwa, Japan
⁷ Clinical Hospital No. 2, Rzeszow, Poland
⁸ Brigham and Women´s Hospital, Boston, United States
⁹ Alimentiv Inc, London, Canada
¹⁰ Icahn School of Medicine at Mount Sinai, New York, United States

Topic
IBD

Session
PP 05 IBD (Posters)

Conference
UEG Week 2023

Citation
United European Gastroenterology Journal 2023; 11 (Supplement 8)